News Agency
The Times

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

  • Written by PR Newswire
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

Trial results anticipated in early Q3 this year

SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept,...

Read more: Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion